P.3.c.017 Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic induced hyperprolactinemia

Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials.

Aripiprazole versus other atypical antipsychotics for schizophrenia

Khanna

Komossa

Rummel‐Kluge³

et al. 2013

Aripiprazole versus other atypical antipsychotics for schizophrenia

Khanna

Suo

Komossa

et al. 2014

Aripiprazole versus typicals for schizophrenia

Bhattacharjee¹,

El‐Sayeh²

2008

Aripiprazole is not much different from typical antipsychotic drugs with respect to efficacy. However it presents significant advantages in terms of tolerability due to its favourable adverse effects profile. This might enhance its effectiveness in encouraging compliance. Clearly reported pragmatic short, medium and long term randomised controlled trials are required to replicate and validate these findings and determine the position of aripiprazole in everyday clinical practice.